Outlook Therapeutics (OTLK) Retained Earnings: 2015-2020
Historic Retained Earnings for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to -$279.8 million.
- Outlook Therapeutics' Retained Earnings fell 14.49% to -$279.8 million in Q2 2020 from the same period last year, while for Jun 2020 it was -$279.8 million, marking a year-over-year decrease of 14.49%. This contributed to the annual value of -$254.5 million for FY2019, which is 17.65% down from last year.
- Per Outlook Therapeutics' latest filing, its Retained Earnings stood at -$279.8 million for Q2 2020, which was down 1.09% from -$276.8 million recorded in Q1 2020.
- In the past 5 years, Outlook Therapeutics' Retained Earnings registered a high of -$114.5 million during Q1 2016, and its lowest value of -$279.8 million during Q2 2020.
- For the 3-year period, Outlook Therapeutics' Retained Earnings averaged around -$241.2 million, with its median value being -$242.2 million (2019).
- Data for Outlook Therapeutics' Retained Earnings shows a maximum YoY crashed of 56.67% (in 2016) over the last 5 years.
- Outlook Therapeutics' Retained Earnings (Quarterly) stood at -$166.5 million in 2016, then declined by 13.00% to -$188.1 million in 2017, then decreased by 22.09% to -$229.7 million in 2018, then declined by 18.02% to -$271.1 million in 2019, then declined by 14.49% to -$279.8 million in 2020.
- Its Retained Earnings stands at -$279.8 million for Q2 2020, versus -$276.8 million for Q1 2020 and -$271.1 million for Q4 2019.